Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

rct

• numeric_findings[1]

  {"unit":null,"label":"reported_value","value_text":"2.4"}

  View evidence

  • CONCLUSIONS · CONCLUSIONS:S001

    “”

• numeric_findings[2]

  {"unit":null,"label":"reported_value","value_text":"45"}

  View evidence

  • METHODS · METHODS:S001

    “”

• numeric_findings[3]

  {"unit":null,"label":"reported_value","value_text":"1"}

  View evidence

  • METHODS · METHODS:S002

    “”

• population

  {"description":"Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes.","sample_size":null,"exclusion_summary":null,"inclusion_summary":null}

  View evidence

  • BACKGROUND · BACKGROUND:S001

    “”

• authors_conclusion
• comparator
• extension.rct_extension.allocation_ratio
• extension.rct_extension.blinding
• extension.rct_extension.itt_or_per_protocol
• extension.rct_extension.primary_endpoint
• extension.rct_extension.randomization_method
• extension.rct_extension.sample_size_arms
• intervention
• key_results
• limitations
• primary_outcome
• safety_findings

• PharmaLens analyzed the title, abstract, and available metadata—not the full text.
• This page is not medical advice.
• Scores and ranks shown in search are query-relative relevance only — not evidence quality.
• Similarity neighbors do not imply support or contradiction.
• Cover media kind: deterministic_cover
• Extraction schema: pharmalens.article-intelligence.v1
• Revision: 1

• Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
• Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.
• Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
• Lecanemab in Early Alzheimer's Disease.
• Evidence Neighborhood preview: Lecanemab in Early Alzheimer's Disease.
• Evidence Neighborhood preview: Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
• Evidence Neighborhood preview: Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.
• Evidence Neighborhood preview: Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.

Relatedness is similarity or shared entities — not support or contradiction.